Study of a new treatment for high-grade bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have high-grade bladder cancer that has not spread into the muscle layer and you have tried BCG treatment (at least 5 out of 6 doses).
- You cannot have or have decided not to have surgery to remove your bladder.
- Your doctor thinks you are healthy enough to live more than 2 years and your daily activity level is not severely limited.
- You do not have active cancer in the upper urinary tract or prostate, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This study tests a more targeted way to treat low-grade bladder cancer using chemotherapy placed directly into the bladder. Before treatment, your cancer cells are grown in the lab to see which drug works best for you.
This study compares a new combination of chemotherapy drugs delivered directly into the bladder versus standard treatment for people with non-muscle invasive bladder cancer that has returned or not responded to prior therapy. It aims to see if the new treatment helps prevent the cancer from coming back.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.